ChemoCentryx Company Profile (NASDAQ:CCXI)

About ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx logoChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CCXI
  • CUSIP: 16383L10
  • Web:
  • Market Cap: $405.62 million
  • Outstanding Shares: 48,173,000
Average Prices:
  • 50 Day Moving Avg: $7.14
  • 200 Day Moving Avg: $7.29
  • 52 Week Range: $3.95 - $9.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.21
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $20.17 million
  • Price / Sales: 20.97
  • Book Value: $0.96 per share
  • Price / Book: 9.15
  • EBIDTA: ($31,340,000.00)
  • Return on Equity: -58.48%
  • Return on Assets: -21.03%
  • Current Ratio: 2.82%
  • Quick Ratio: 2.82%
  • Average Volume: 98,402 shs.
  • Beta: 1.5
  • Short Ratio: 26.55

Frequently Asked Questions for ChemoCentryx (NASDAQ:CCXI)

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. View ChemoCentryx's Earnings History.

Where is ChemoCentryx's stock going? Where will ChemoCentryx's stock price be in 2017?

3 analysts have issued 12 month target prices for ChemoCentryx's stock. Their predictions range from $11.00 to $11.00. On average, they anticipate ChemoCentryx's share price to reach $11.00 in the next year. View Analyst Ratings for ChemoCentryx.

What are analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:

  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (3/20/2017)
  • 2. Cowen and Company analysts commented, "ChemoCentryx reported a Q4:16 net loss of $8MM and a pro-forma cash balance of." (3/15/2017)
  • 3. J P Morgan Chase & Co analysts commented, "ChemoCentryx announced a GAAP loss per share of $0.22. Overall, highlights on the call were incremental and the company continues to make steady progress across key programs. Of note, related to CCX168 in ANCA-associated vasculitis (AAV), the company has had initial discussions with US / EU regulatory bodies. Along with the recent strategic partnering with Vifor Pharma, we believe that the potential advancement of CCX168 into phase 3 would provide further validation to the phase 2 datasets (phase 3 program expected to start by YE16; see our thoughts from CLEAR and CLASSIC studies here and here). Looking forward beyond CCX168 in AAV, there are additional catalysts worth monitoring, including early data from CCX168 in aHUS (late-2016; potentially ASN in November) and ORR (3Q) / initial PFS (4Q) data for CCX872." (8/9/2016)

Who are some of ChemoCentryx's key competitors?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:

  • Thomas J. Schall Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Susan M. Kanaya, Executive Vice President, Chief Financial and Administrative Officer, Secretary
  • Petrus J. Bekker M.D., Ph.D., Senior Vice President - Clinical and Medical Affairs
  • Israel F. Charo M.D., Ph.D., Senior Vice President - Research
  • Markus J. Cappel Ph.D., Chief Business Officer, Treasurer
  • Roger C. Lucas Ph.D., Lead Independent Director
  • Henry A. McKinnell Jr., Ph.D., Director
  • Thomas A. Edwards J.D., Independent Director
  • Joseph M. Feczko M.D., Independent Director
  • Geoffrey M. Parker, Independent Director

Who owns ChemoCentryx stock?

ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.49%), Acadian Asset Management LLC (1.77%), Renaissance Technologies LLC (1.28%), Iguana Healthcare Management LLC (0.52%), Oxford Asset Management (0.45%) and Geode Capital Management LLC (0.41%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya, Thomas A Edwards and Value Fund L P Biotechnology. View Institutional Ownership Trends for ChemoCentryx.

Who sold ChemoCentryx stock? Who is selling ChemoCentryx stock?

ChemoCentryx's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., City Financial Investment Co Ltd, Oxford Asset Management, Bank of America Corp DE, Bogle Investment Management L P DE, Banque Pictet & Cie SA, Iguana Healthcare Management LLC and Citadel Advisors LLC. Company insiders that have sold ChemoCentryx stock in the last year include Markus J Cappel, Petrus Bekker and Roger C Lucas. View Insider Buying and Selling for ChemoCentryx.

Who bought ChemoCentryx stock? Who is buying ChemoCentryx stock?

ChemoCentryx's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Spark Investment Management LLC, EcoR1 Capital LLC, Thrivent Financial For Lutherans, Vanguard Group Inc., Eagle Global Advisors LLC and American Century Companies Inc.. Company insiders that have bought ChemoCentryx stock in the last two years include Geoffrey M Parker and Thomas A Edwards. View Insider Buying and Selling for ChemoCentryx.

How do I buy ChemoCentryx stock?

Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of ChemoCentryx stock can currently be purchased for approximately $8.78.

MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ChemoCentryx (NASDAQ:CCXI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $11.00 (25.28% upside)

Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/15/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform -> OutperformN/AView Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for ChemoCentryx (NASDAQ:CCXI)
Earnings by Quarter for ChemoCentryx (NASDAQ:CCXI)
Earnings History by Quarter for ChemoCentryx (NASDAQ CCXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.26)($0.12)$8.23 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.22)($0.16)$4.89 millionViewN/AView Earnings Details
11/7/2016Q3($0.08)($0.15)ViewListenView Earnings Details
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details
11/5/2014Q3 2014($0.29)($0.25)ViewN/AView Earnings Details
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details
3/13/2014($0.25)($0.22)$1.37 million$0.73 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)
Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS


Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ChemoCentryx (NASDAQ:CCXI)
Insider Ownership Percentage: 26.80%
Institutional Ownership Percentage: 49.36%
Insider Trades by Quarter for ChemoCentryx (NASDAQ:CCXI)
Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)
Insider Trades by Quarter for ChemoCentryx (NASDAQ:CCXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Roger C LucasDirectorSell4,000$7.31$29,240.00View SEC Filing  
1/3/2017Markus J CappelInsiderSell26,821$7.51$201,425.71View SEC Filing  
12/16/2016Petrus BekkerInsiderSell8,712$8.74$76,142.88View SEC Filing  
12/5/2016Petrus BekkerInsiderSell30,000$8.50$255,000.00View SEC Filing  
11/22/2016Petrus BekkerInsiderSell1,250$8.30$10,375.00View SEC Filing  
11/11/2016Petrus BekkerInsiderSell33,332$8.00$266,656.00View SEC Filing  
9/1/2016Roger C LucasDirectorSell4,000$5.07$20,280.00View SEC Filing  
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.16View SEC Filing  
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.00View SEC Filing  
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.00View SEC Filing  
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.00View SEC Filing  
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.00View SEC Filing  
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.00View SEC Filing  
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ChemoCentryx (NASDAQ:CCXI)
Latest Headlines for ChemoCentryx (NASDAQ:CCXI)
DateHeadline logo Analysts Anticipate ChemoCentryx, Inc. (CCXI) to Announce -$0.19 EPS - June 22 at 4:24 PM logoETFs with exposure to ChemoCentryx, Inc. : June 15, 2017 - June 15 at 6:00 PM logoChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : June 8, 2017 - June 8 at 5:11 PM logoOral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS) - June 6 at 4:25 PM logoZacks: Brokerages Anticipate ChemoCentryx Inc (CCXI) Will Post Earnings of -$0.19 Per Share - May 29 at 12:28 PM logoChemoCentryx to Present at Two Upcoming Investor Conferences - May 24 at 9:01 AM logoChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) - May 23 at 12:53 PM logoChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : May 15, 2017 - May 16 at 12:48 PM logoChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : May 12, 2017 - May 12 at 4:45 PM logoEdited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT - May 11 at 9:50 PM logoChemoCentryx Inc (CCXI) Announces Quarterly Earnings Results - May 11 at 6:35 PM logoChemoCentryx's (CCXI) CEO Thomas Schall on Q1 2017 Results - Earnings Call Transcript - May 11 at 2:37 AM logoChemoCentryx reports 1Q loss - May 10 at 9:37 PM logoInvestor Network: Chemocentryx, Inc. to Host Earnings Call - May 10 at 4:23 PM logoChemoCentryx Reports First Quarter 2017 Financial Results - May 10 at 4:23 PM logo Brokerages Anticipate ChemoCentryx Inc (CCXI) to Post -$0.21 Earnings Per Share - May 9 at 12:58 AM logo-$0.21 EPS Expected for ChemoCentryx Inc (CCXI) This Quarter - May 4 at 1:32 AM logoChemoCentryx Inc (CCXI) Director Sells $29,240.00 in Stock - May 4 at 1:27 AM logoSomewhat Favorable News Coverage Extremely Likely to Impact ChemoCentryx (CCXI) Share Price - April 30 at 2:42 PM logoChemoCentryx (CCXI) Getting Somewhat Negative Press Coverage, Analysis Shows - April 27 at 5:38 PM logoChemoCentryx (CCXI) Earning Somewhat Positive News Coverage, Report Finds - April 15 at 11:21 AM logoChemoCentryx Inc (CCXI) Expected to Announce Earnings of -$0.21 Per Share - April 12 at 8:22 PM logoShort Interest in ChemoCentryx Inc (CCXI) Drops By 1.3% - April 8 at 7:08 AM logoChemoCentryx Inc (CCXI) Coverage Initiated by Analysts at JMP Securities - March 26 at 1:42 PM logoChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G) - March 22 at 3:59 PM logo8:31 am ChemoCentryx confirms that the FDA granted orphan drug designation for avacopan in the treatment of patients with C3 glomerulopathy - March 22 at 3:59 PM logoZacks Investment Research Downgrades ChemoCentryx Inc (CCXI) to Hold - March 20 at 5:37 PM logoChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results - March 14 at 9:06 PM logoCHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi - March 14 at 9:06 PM logoZacks Investment Research Upgrades ChemoCentryx Inc (CCXI) to “Buy” - March 13 at 8:23 AM logoCHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 2 at 9:28 PM logoChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017 - March 1 at 10:40 AM logoChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference - February 28 at 8:35 AM logoCoverage initiated on ChemoCentryx by JMP Securities - February 22 at 12:13 PM logoVifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases - February 14 at 2:53 AM logoChemoCentryx (CCXI) Announces Presentation of Data from ... - - January 21 at 9:16 PM logoChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq ... - Nasdaq - January 21 at 9:16 PM logoChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor - January 20 at 10:20 PM logoChemoCentryx (CCXI) Announces Presentation of Data from Ongoing Phase Ib Trial of CCR2 Inhibitor CCX872 at ASCO - January 20 at 5:20 PM logoChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco - January 20 at 5:20 PM logoChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer - January 20 at 5:20 PM logo3:34 pm ChemoCentryx presents from a continuing open-label, single-arm Phase Ib clinical trial of CCX872 at ASCO 2017; plans to further investigate CCX872 in combination with a checkpoint inhibitor. - January 20 at 5:20 PM logoChemoCentryx (CCXI) Offers Update, Development Strategy - January 9 at 5:21 PM logoChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases - January 9 at 5:20 PM logoChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference - January 4 at 5:13 PM



ChemoCentryx (CCXI) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff